Endogenous endophthalmitis in post-COVID-19 patients: a case report.
SARS-CoV-2 virus
case study
coronavirus disease 2019
endogenous
endophthalmitides
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
15
03
2023
accepted:
01
07
2023
medline:
9
8
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
Ocular involvement in coronavirus disease 2019 (COVID-19) can be due to direct viral invasion or indirectly due to an immunosuppressed state. Prolonged hospitalization also makes them susceptible to various secondary infections. The purpose of this case report is to report two rare cases of endogenous endophthalmitis (EE) in COVID-19 recovered patients. Two patients who were hospitalized and received treatment for COVID-19 pneumonia with remdesivir and systemic steroids presented with decreased vision. The first case had a severe anterior chamber reaction with a hypopyon and dense exudates in the vitreous. The second case had cells and flare in the anterior chamber and exudates in the vitreous. They were diagnosed with EE and underwent a diagnostic vitreous tap followed by pars plana vitrectomy and intravitreal antibiotic and steroid. The culture of vitreous fluid was negative for any bacteria and fungus in both cases. However, the first case demonstrated Severe COVID-19 patients who are hospitalized, receive systemic steroid and have associated comorbidities like diabetes mellitus are at high risk of EE. Delay in diagnosis and appropriate treatment in these patients leads to poor visual outcome.
Identifiants
pubmed: 37554872
doi: 10.1097/MS9.0000000000001051
pii: AMSU-D-23-00555
pmc: PMC10406071
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4137-4141Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
BMJ Case Rep. 2021 Apr 21;14(4):
pubmed: 33883113
Indian J Ophthalmol. 2021 May;69(5):1322-1325
pubmed: 33913891
BMC Ophthalmol. 2020 Apr 7;20(1):138
pubmed: 32264861
J Ophthalmol. 2020 Aug 27;2020:4827304
pubmed: 32963819
Retina. 2021 Aug 1;41(8):1709-1714
pubmed: 33734193
Indian J Ophthalmol. 2021 May;69(5):1275-1282
pubmed: 33913876
In Vivo. 2020 Jun;34(3 Suppl):1619-1628
pubmed: 32503820
PLoS One. 2020 Dec 3;15(12):e0243346
pubmed: 33270751
Indian J Ophthalmol. 2021 Jul;69(7):1909-1914
pubmed: 34146056
Eye (Lond). 2011 Jan;25(1):66-72
pubmed: 20966972
Int J Surg. 2020 Dec;84:226-230
pubmed: 33181358
J Crit Care. 2012 Dec;27(6):746.e9-22
pubmed: 22999481
SN Compr Clin Med. 2021;3(9):1843-1847
pubmed: 34124585
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Ocul Immunol Inflamm. 2021 May 19;29(4):726-729
pubmed: 34255587